1h Free Analyst Time
The treatment resistant depression therapeutics market is forecasted to grow by USD 2.06 billion during 2024-2029, accelerating at a CAGR of 6.1% during the forecast period. The report on the treatment resistant depression therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of depression, focus on rapid-acting antidepressants, and investments in mental health.
The treatment resistant depression therapeutics market is segmented as below:
By Distribution Channel
- Offline
- Online
By Type
- Antidepressants
- NMDA
- Antipsychotics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the treatment resistant depression therapeutics market covers the following areas:
- Treatment Resistant Depression Therapeutics Market sizing
- Treatment Resistant Depression Therapeutics Market forecast
- Treatment Resistant Depression Therapeutics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Distribution Channel
9 Market Segmentation by Type
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global treatment resistant depression therapeutics market: AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Public Ltd. Co., AstraZeneca Plc, Axsome Therapeutics Inc., Eli Lilly and Co., Evotec SE, H Lundbeck AS, Intra-Cellular Therapies Inc, Johnson and Johnson Inc., Numinus Wellness Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sage Therapeutics Inc, Stella MSO LLC dba Field Trip Health, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., and Vistagen Therapeutics Inc.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emergence of ai in drug development."
According to the report, one of the major drivers for this market is the high prevalence of depression.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Alkermes Public Ltd. Co.
- AstraZeneca Plc
- Axsome Therapeutics Inc.
- Eli Lilly and Co.
- Evotec SE
- H Lundbeck AS
- Intra-Cellular Therapies Inc
- Johnson and Johnson Inc.
- Numinus Wellness Inc
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Sage Therapeutics Inc
- Stella MSO LLC dba Field Trip Health
- Sumitomo Pharma Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vistagen Therapeutics Inc
